Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
William J. Meury
CEOWilliam J. Meury
Employees
2,844
Employees2,844
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,844
Employees2,844

INCY Key Statistics

Market cap
26.04B
Market cap26.04B
Price-Earnings ratio
15.74
Price-Earnings ratio15.74
Dividend yield
Dividend yield
Average volume
1.39M
Average volume1.39M
High today
$127.24
High today$127.24
Low today
$126.50
Low today$126.50
Open price
$125.00
Open price$125.00
Volume
1.69K
Volume1.69K
52 Week high
$132.60
52 Week high$132.60
52 Week low
$81.09
52 Week low$81.09

Stock Snapshot

The current Incyte(INCY) stock price is $126.95, with a market capitalization of 26.04B. The stock trades at a price-to-earnings (P/E) ratio of 15.74.

On 2026-08-20, Incyte(INCY) stock traded between a low of $126.50 and a high of $127.24. Shares are currently priced at $126.95, which is +0.4% above the low and -0.2% below the high.

The Incyte(INCY)'s current trading volume is 1.69K, compared to an average daily volume of 1.39M.

In the last year, Incyte(INCY) shares hit a 52-week high of $132.60 and a 52-week low of $81.09.

In the last year, Incyte(INCY) shares hit a 52-week high of $132.60 and a 52-week low of $81.09.

INCY News

TipRanks 2h
Incyte initiated with a Buy at Canaccord

Canaccord initiated coverage of Incyte (INCY) with a Buy rating and $152 price target Published first on TheFly – the ultimate source for real-time, market-mov...

TipRanks 3h
Incyte Target Unchanged at $150 as Kapoor Reiterates Buy on Strong Early KRAS G12D Pancreatic Cancer Data

Incyte, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on the...

Simply Wall St 21h
Is Incyte Above Fair Value After A 91% Run?

Incyte stock has delivered a strong 90.6% return over the past three years, yet on broad valuation checks it no longer looks like an obvious bargain. Over the...

Is Incyte Above Fair Value After A 91% Run?

Analyst ratings

53%

of 30 ratings
Buy
40%
Hold
53.3%
Sell
6.7%

More INCY News

TipRanks 22h
Incyte ‘734 update likely to be ‘very competitive,’ says RBC Capital

Incyte (INCY) is expected to report updated data for KRAS G12D inhibitor ‘734, in combination with mFOLFIRINOX and GemNabP, at ESMO in October, with previous da...

TipRanks 3d
Incyte price target raised to $130 from $110 at Piper Sandler

Piper Sandler analyst Allison Bratzel raised the firm’s price target on Incyte (INCY) to $130 from $110 and keeps an Overweight rating on the shares following q...

TipRanks 5d
Top Incyte Executive Makes Major Move With Fresh Stock Sale

New insider activity at Incyte ( (INCY) ) has taken place on August 14, 2026. Claim 55% Off TipRanks Unlock powerful investing tools with TipRanks Premium to ma...

TipRanks 6d
Incyte Earnings Call: Growth Surges, Costs Climb

Incyte ((INCY)) has held its Q2 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock powerful investing tools with TipRanks...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.